Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors

Abstract

Hemophilia B, or factor IX deficiency, is an X-linked recessive disorder occurring in about 1 in 25,000 males. Affected individuals are at risk for spontaneous bleeding into many organs; treatment mainly consists of the transfusion of clotting factor concentrates prepared from human blood or recombinant sources after bleeding has started. Small- and large-animal models have been developed and/or characterized that closely mimic the human disease state. As a preclinical model for gene therapy, recombinant adeno-associated viral vectors containing the human or canine factor IX cDNAs were infused into the livers of murine and canine models of hemophilia B, respectively. There was no associated toxicity with infusion in either animal model. Constitutive expression of factor IX was observed, which resulted in the correction of the bleeding disorder over a period of over 17 months in mice. Mice with a steady-state concentration of 25% of the normal human level of factor IX had normal coagulation. In hemophilic dogs, a dose of rAAV that was approximately 1/10 per body weight that given to mice resulted in 1% of normal canine factor IX levels, the absence of inhibitors, and a sustained partial correction of the coagulation defect for at least 8 months.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Structures of the rAAV vectors.
Figure 2: Tissue distribution of the vector genome over time after gene transfer in mice.
Figure 3: Gene therapy in hemophilia B mice.
Figure 4: Western blot analysis for anti-hFIX antibodies in rAAV treated mice.
Figure 5: Gene therapy in hemophilia B dogs.

Similar content being viewed by others

References

  1. Lin, H.-F., Maeda, N., Smithies, O., Straight, D.L. & Stafford, D.W. A Coagulation Factor IX-Deficient Mouse Model for Human Hemophilia B. Blood 90, 3962– 3966 (1997).

    CAS  PubMed  Google Scholar 

  2. Bi, L. et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nature Gen. 10, ( 1995).

  3. Wang, L. et al. A factor IX-deficient mouse model for hemophilia B gene therapy. Med. Sci. 94, 11563–11566 (1997).

    CAS  Google Scholar 

  4. Kundu, R.K. et al. Targeted Inactivation of the Coagulation Factor IX Gene Causes Hemophilia B. in Mice. Blood 92, 68– 174 (1998).

    Google Scholar 

  5. Nichols, T.C. et al. The roles of von Willebrand factor and factor VIII in arterial thrombosis: studies in canine von Willebrand disease and hemophilia A. Blood 81, 2644–2651 ( 1993).

    CAS  PubMed  Google Scholar 

  6. Giles, A.R., Tinlin, S. & Greenwood, R. A canine model of hemophilic (factor VIII:C deficiency) bleeding. Blood 60, 727– 730 (1982).

    CAS  PubMed  Google Scholar 

  7. Kingdon, H.S. & Hassell, T.M. Hemophilic dog model for evaluating therapeutic effectiveness of plasma protein fractions. Blood 58, 868–872 (1981).

    CAS  PubMed  Google Scholar 

  8. Mauser, A.E., Whitlark, J. Whitney, K.M. & Lothrop, Jr., C.D. A deletion mutation causes hemophilia B in Lhasa Apso dogs. Blood 88, 3451–3455 (1996).

    CAS  PubMed  Google Scholar 

  9. Brinkhous, K.M. et al. Pharmacokinetics and pharmacodynamics of a B-domain deleted recombinant factor VIII derivative, r-VIII SQ, in canine hemophilia. Thromb. Haemost. 69, 852 (1993 ).

    Google Scholar 

  10. Griggs, T.R., Webster, W.P., Cooper, H.A., Wagner, R.H. & Brinkhous, K.M. Von Willebrand Factor: Gene dosage relationships and transfusion response in bleeder swine - a new bioassay. Proc. Natl. Acad. Sci. USA 71, 2087– 2090 (1974).

    Article  CAS  Google Scholar 

  11. Neuenschwander, S. & Pliska, V. 1994. Factor VIII in blood plasma of haemophilic sheep: analysis of clotting time-plasma dilution curves. Haemostasis 24, 27– 35 (1994).

    CAS  PubMed  Google Scholar 

  12. Dai, Y. et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Med. Sci. 92, 1401– 1405 (1995).

    CAS  Google Scholar 

  13. Herzog, R.W. et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl. Acad. Sci. USA 94, 5804– 5809 (1997).

    Article  CAS  Google Scholar 

  14. Yao, S.N., Smith, K.J. & Kurachi, K. Primary myoblast-mediated gene transfer: persistent expression of human factor IX in mice. Gene Ther. 1 , 99–107 (1994).

    CAS  PubMed  Google Scholar 

  15. Yao, S.N., & Kurachi, K. Expression of human factor IX in mice after injection of genetically modified myoblasts. Proc. Natl. Acad. Sci. USA 89, 3357–3361 (1992).

    Article  CAS  Google Scholar 

  16. Rosenberg, J.B. et al. Intracellular trafficking of factor VIII to von Willebrand factor granules. J. Clin. Invest. 101, 613 –624 (1998).

    Article  CAS  Google Scholar 

  17. Ewenstein, B.M. et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 89, 1115– 1116 (1997).

    CAS  PubMed  Google Scholar 

  18. Warrier, I. et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J. Pediatr. Hematol. Oncol. 19, 23-27 (1997).

    Article  CAS  Google Scholar 

  19. Smith, T.A. et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nature Genet. 5, 397–402 (1993).

    Article  CAS  Google Scholar 

  20. Kung, S.-H. et al. Human Factor IX Corrects the Bleeding Diathesis of Mice with Hemophilia B. Blood 91, 784–790.

  21. Kay, M.A. et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc. Natl. Acad. Sci. USA 91, 2353–2357 (1994).

    Article  CAS  Google Scholar 

  22. Kay, M.A. et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science 262 , 117–119 (1993).

    Article  CAS  Google Scholar 

  23. Snyder, R.O. et al. Persistent and therapeutic concnetrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nature Genet. 16, 270-275 ( 1997).

    Article  CAS  Google Scholar 

  24. Miao, C.H. et al. The kinetics of rAAV integration in the liver. Nature Genet. 19, 13–15 (1998).

    Article  CAS  Google Scholar 

  25. Nakai, H. et al. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 91, 4600–4607 (1998).

    CAS  PubMed  Google Scholar 

  26. Brinkhous, K.M., Landen, C.N. & Read, M.S. Evaluation of sensitivity of whole blood clotting time (WBCT), partial thromboplastin time (PTT), and F.IX one-stage bioassay tests with low plasma F.IX levels observed with transfusion or gene therapy in canine hemophilia B. Blood 82, suppl 1 :592a (1993).

    Google Scholar 

  27. Samulski, R.J., Chang, L.-S. & Shenk, T. Helper-free stocks of recombinant adeno-associated viruses: Normal intergation does not require viral gene expression. J. Virol. 63, 3822–3828 ( 1989).

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Dranoff, G. et al. Vaccination with irridated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulate potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539–3543 ( 1993).

    Article  CAS  Google Scholar 

  29. Zolotukhin, S., Potter, M., Hauswirth, W.W., Guy, J. & Muzyczka, N. A "humanized" green fluorescent protein cDNA adapted for high-level gene expression in mammalian cells. J. Virol. 70, 4646–4654 (1996).

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Li, J., Samulski, R.J. & Xiao, X. Role for highly regulated rep gene expression in adeno-associated virus vector production. J. Virol. (in the press).

  31. Kasper, C.K. & Pool, J.G. Measurement of milid factor VIII inhibitors in Bethesda units. Thromb. Diathesis Haemorrhagica 34, 875–876 (1975).

    CAS  Google Scholar 

Download references

Acknowledgements

We thank S. Powell, V. Vimal, B. Winther, B. Kaspar, T. Dull, D. Colvin, R. Lazar, M. Moskalenko, Y.-L. Li, R. Raymer and P. McElveen for technical assistance, and L. Naldini for comments. This work was supported by NIH grants, HL53682 (M.A.K.) and HL01648 (U.N.C.).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark A. Kay.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Snyder, R., Miao, C., Meuse, L. et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 5, 64–70 (1999). https://doi.org/10.1038/4751

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/4751

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing